Piramal Pharma Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. Alongside strong financial disclosures, the company confirmed the re-appointment of key leadership figures, including Chairperson Ms. Nandini Piramal and Executive Director Mr. Peter DeYoung. Additionally, the Board has appointed Mr. Maneesh Sharma as the new Company Secretary and Compliance Officer and approved a change to the company’s registered office address.
FY26 Financial Highlights
For the financial year ended March 31, 2026, Piramal Pharma Limited reported standalone revenue from operations of ₹4,782.01 crore, with a profit after tax of ₹700.01 crore. On a consolidated basis, the company reported annual revenue of ₹8,869.08 crore for the same period. The board has confirmed that these results have been issued with an unmodified opinion by the statutory auditors, ensuring transparency and accuracy in reporting.
Strategic Leadership Renewals
The Board has recommended several high-level leadership renewals to ensure continuity in strategic vision. Ms. Nandini Piramal has been re-appointed as Whole-Time Director, designated as Executive Director and Chairperson, for a period of three consecutive years effective from April 1, 2027. Similarly, Mr. Peter DeYoung has been re-appointed as Whole-Time Director, designated as Executive Director, for three consecutive years effective from October 6, 2026. Furthermore, the Board approved a second term of five years for Independent Directors Mr. Sridhar Gorthi and Mr. Peter Stevenson, both effective from March 30, 2027.
Corporate Governance and Operational Updates
As part of its organizational strengthening, the company announced the appointment of Mr. Maneesh Sharma as the new Company Secretary and Compliance Officer, effective April 29, 2026, succeeding Ms. Pratibha Mishra. Additionally, to better align its corporate presence, the company is shifting its registered office to Ananta Building, Piramal Corporate Park, Kurla (West), Mumbai, with the change becoming effective on April 30, 2026. These changes underscore the company’s commitment to robust governance and operational efficiency.
Source: BSE
